Baldry Mark 4
4 · X4 Pharmaceuticals, Inc · Filed Nov 4, 2022
Insider Transaction Report
Form 4
Baldry Mark
Chief Commercial Officer
Transactions
- Award
Stock Option (right to buy)
2022-11-03$1.89/sh+341,000$644,490→ 341,000 totalExercise: $1.89Exp: 2032-11-03→ Common Stock (341,000 underlying)
Footnotes (1)
- [F1]25% of the shares subject to the option shall vest on November 3, 2023, with the remainder vesting in equal installments of 2.0833% of the shares subject to the option each successive month thereafter for a period of 36 months, subject to the Reporting Person continuing to provide services through each such date.